The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

Hpic1  -  haloperidol-induced catalepsy 1

Mus musculus

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hpic1


Psychiatry related information on Hpic1


High impact information on Hpic1


Chemical compound and disease context of Hpic1


Biological context of Hpic1


Anatomical context of Hpic1


Associations of Hpic1 with chemical compounds


Regulatory relationships of Hpic1


Other interactions of Hpic1


Analytical, diagnostic and therapeutic context of Hpic1


  1. Fyn is required for haloperidol-induced catalepsy in mice. Hattori, K., Uchino, S., Isosaka, T., Maekawa, M., Iyo, M., Sato, T., Kohsaka, S., Yagi, T., Yuasa, S. J. Biol. Chem. (2006) [Pubmed]
  2. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Depoortere, R., Boulay, D., Perrault, G., Bergis, O., Decobert, M., Françon, D., Jung, M., Simiand, J., Soubrié, P., Scatton, B. Neuropsychopharmacology (2003) [Pubmed]
  3. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. Speiser, Z., Levy, R., Cohen, S. J. Neural Transm. Suppl. (1998) [Pubmed]
  4. Catalepsy induced by manidipine, a calcium channel blocker, in mice. Haraguchi, K., Ito, K., Sawada, Y., Iga, T. J. Pharm. Pharmacol. (1996) [Pubmed]
  5. Behavioural effect of Pavetta crassipes extract on rodents. Amos, S., Akah, P.A., Enwerem, N., Chindo, B.A., Hussaini, I.M., Wambebe, C., Gamaniel, K. Pharmacol. Biochem. Behav. (2004) [Pubmed]
  6. Behavioral effects of acute and long-term administration of catnip (Nepeta cataria) in mice. Massoco, C.O., Silva, M.R., Gorniak, S.L., Spinosa, M.S., Bernardi, M.M. Veterinary and human toxicology. (1995) [Pubmed]
  7. Effect of Brahmi Rasayan on the central nervous system. Shukia, B., Khanna, N.K., Godhwani, J.L. Journal of ethnopharmacology. (1987) [Pubmed]
  8. Neurotensin-deficient mice show altered responses to antipsychotic drugs. Dobner, P.R., Fadel, J., Deitemeyer, N., Carraway, R.E., Deutch, A.Y. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  9. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Ethier, I., Beaudry, G., St-Hilaire, M., Milbrandt, J., Rouillard, C., Lévesque, D. Neuropsychopharmacology (2004) [Pubmed]
  10. Genetics, haloperidol, and the Fos response in the basal ganglia: a comparison of the C57BL/6J and DBA/2J inbred mouse strains. Patel, N., Hitzemann, B., Hitzemann, R. Neuropsychopharmacology (1998) [Pubmed]
  11. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Siuciak, J.A., Chapin, D.S., Harms, J.F., Lebel, L.A., McCarthy, S.A., Chambers, L., Shrikhande, A., Wong, S., Menniti, F.S., Schmidt, C.J. Neuropharmacology (2006) [Pubmed]
  12. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Boulay, D., Depoortere, R., Oblin, A., Sanger, D.J., Schoemaker, H., Perrault, G. Eur. J. Pharmacol. (2000) [Pubmed]
  13. Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Broekkamp, C.L., Oosterloo, S.K., Berendsen, H.H., van Delft, A.M. Naunyn Schmiedebergs Arch. Pharmacol. (1988) [Pubmed]
  14. Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice. Kinoshita, H., Hasegawa, T., Kameyama, T., Yamamoto, I., Nabeshima, T. Neurosci. Lett. (1994) [Pubmed]
  15. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Kobayashi, T., Araki, T., Itoyama, Y., Takeshita, M., Ohta, T., Oshima, Y. Life Sci. (1997) [Pubmed]
  16. Detection and mapping of quantitative trait loci for haloperidol-induced catalepsy in a C57BL/6J x DBA/2J F2 intercross. Patel, N.V., Hitzemann, R.J. Behav. Genet. (1999) [Pubmed]
  17. Effect of genetic cross on the detection of quantitative trait loci and a novel approach to mapping QTLs. Hitzemann, R., Demarest, K., Koyner, J., Cipp, L., Patel, N., Rasmussen, E., McCaughran, J. Pharmacol. Biochem. Behav. (2000) [Pubmed]
  18. Further studies on the relationship between dopamine cell density and haloperidol-induced catalepsy. Hitzemann, B., Dains, K., Kanes, S., Hitzemann, R. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  19. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. McCaughran, J., Mahjubi, E., Decena, E., Hitzemann, R. Psychopharmacology (Berl.) (1997) [Pubmed]
  20. Effect of manipulation of the GABA system on dopamine-related behaviors. Sandoval, M.R., Palermo-Neto, J. Braz. J. Med. Biol. Res. (1995) [Pubmed]
  21. Evidence for a cholinergic role in haloperidol-induced catalepsy. Klemm, W.R. Psychopharmacology (Berl.) (1985) [Pubmed]
  22. Comparison of the effects of three indirect dopamine agonists, GK 13, GBR 12783 and dexamphetamine on behavioural tests involving central catecholaminergic transmissions. Duterte-Boucher, D., Kamenka, J.M., Costentin, J. Psychopharmacology (Berl.) (1990) [Pubmed]
  23. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. Worms, P., Kan, J.P., Wermuth, C.G., Roncucci, R., Bizière, K. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  24. ST 1535: a preferential A2A adenosine receptor antagonist. Stasi, M.A., Borsini, F., Varani, K., Vincenzi, F., Di Cesare, M.A., Minetti, P., Ghirardi, O., Carminati, P. Int. J. Neuropsychopharmacol. (2006) [Pubmed]
  25. Central action of glucagon. Morawska, D., Sieklucka-Dziuba, M., Kleinrok, Z. Polish journal of pharmacology. (1998) [Pubmed]
  26. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Naidu, P.S., Kulkarni, S.K. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) [Pubmed]
  27. Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study. Worms, P., Kan, J.P., Wermuth, C.G., Biziere, K. Naunyn Schmiedebergs Arch. Pharmacol. (1986) [Pubmed]
  28. Dopamine D2 receptor binding, Drd2 expression and the number of dopamine neurons in the BXD recombinant inbred series: genetic relationships to alcohol and other drug associated phenotypes. Hitzemann, R., Hitzemann, B., Rivera, S., Gatley, J., Thanos, P., Shou, L.L., Williams, R.W. Alcohol. Clin. Exp. Res. (2003) [Pubmed]
  29. Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice. Iwata, S., Izumi, K., Nomoto, M. Pharmacol. Biochem. Behav. (1992) [Pubmed]
  30. Neurobehavioral effects of low level fenvalerate exposure in mice. Mandhane, S.N., Chopde, C.T. Indian J. Exp. Biol. (1997) [Pubmed]
WikiGenes - Universities